Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Plasma levels of beta-2 microglobulin (beta2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive NHL (n=65) and HD (n=37) patients were analyzed in a blinded manner. NHL and HD patients had significantly higher levels of sHLA-1 and beta2M than control subjects. In NHL patients, sHLA-I levels correlated with clinical behavior in a fashion similar to that of beta2M. However, multivariate analysis incorporating beta2M, sHLA-I, and international prognostic index (IPI) indicated that NHL patients with elevated (>312.6mug/100mL) sHLA-I levels had significantly shorter survival, independent of IPI score as well as beta2M. In HD patients, beta2M but not sHLA-I levels were associated with clinical behavior. These findings not only establish the role of sHLA-I as an independent tumor marker in NHL that can be used to stratify patients, but also suggest that beta2M and sHLA-I may reflect different biological processes in HD and NHL. Further studies are needed to assess whether the immunomodulatory properties of sHLA-I may be responsible for its divergence from beta2M as an indicator of clinical behavior in HD.
Albitar
Maher
M
Quest Diagnostics Nichols Institute, 33608 Ortega Highway, Rm#108B, San Juan Capistrano, CA 92690-6130, United States. maher.x.albitar@questdiagnostics.com
Vose
Julie M
JM
Johnson
Marcella M
MM
Do
Kim-Ann
KA
Day
Amanda
A
Jilani
Iman
I
Kantarjian
Hagop
H
Keating
Michael
M
O'Brien
Susan M
SM
Verstovsek
Srdan
S
Armitage
James O
JO
Giles
Francis J
FJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006680:HLA Antigens / Q000097:blood*; D006689:Hodgkin Disease / Q000097:blood* / Q000628:therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D012995:Solubility; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000097:blood*
D014408:Biomarkers, Tumor; D006680:HLA Antigens; D001613:beta 2-Microglobulin